Browse Category

Pharmaceuticals 9 January 2026 - 11 January 2026

Merck Stock (MRK): MMR Split Move Prolongs Cost Review, Delays Quick Revenue Gain
Novartis AG stock stays near a 52-week high after Florida radioligand plant plan

Novartis AG stock stays near a 52-week high after Florida radioligand plant plan

Novartis AG is set to open a radioligand therapy manufacturing plant in Winter Park, Florida, part of its broader $23 billion U.S. production expansion. Shares of the Swiss drugmaker ended Friday up 0.25% at 114.04 Swiss francs, just shy of their 52-week peak of 114.64. CEO Vas Narasimhan described the facility as “an important step,” while Florida’s commerce chief J. Alex Kelly welcomed the move as an opportunity to bring in “world class innovators.”
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

AnaptysBio said it filed a motion asking a U.S. court to dismiss part of a claim by GSK plc’s oncology unit, escalating a dispute over royalties tied to sales of cancer drug Jemperli, a PD-1 inhibitor — a kind of immunotherapy that helps the immune system attack tumours. Tesaro sued AnaptysBio in Delaware in November seeking to terminate a 2014 licence and halve royalty and milestone payments, while AnaptysBio countersued and pointed to trials involving rival PD-1 drugs including Merck’s Keytruda; the case is set for a July 14–17 trial and the court is expected to hear the motion by early March, with royalties under the licence rising to 25% on annual sales above $2.5 billion through patents expiring in 2035-36. GSK did not immediately respond to a request for comment, and its U.S.-listed shares ended Friday up 0.3% at $50.39.
Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon stock edges up after-hours as Amazon Pharmacy adds Novo’s Wegovy pill

Amazon.com shares rose 0.4% in after-hours trading on Friday after Amazon Pharmacy said it has begun offering Novo Nordisk’s Wegovy weight-loss pill via insurance plans as well as a cash-pay option. Customers who qualify and have commercial insurance could pay $25 for a one-month supply, while cash-pay begins at $149; the U.S. FDA approved the pill in December, Amazon said. AMZN last traded at $247.33, after ranging from $242.31 to $247.71 during the session. Novo has said the pill will also be available through CVS and Costco and through telehealth providers including Ro, LifeMD, WeightWatchers and GoodRx.
Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

Eli Lilly stock (LLY) slips as Ventyx deal, Zepbound arthritis data and TuneLab AI tie-up come into view

Eli Lilly and Company shares were down about 0.4% at $1,081 in morning trade on Friday. The drugmaker said this week it will buy autoimmune developer Ventyx Biosciences for $1.2 billion in cash, bringing oral candidates for inflammatory bowel disease into its pipeline. The $14-a-share offer is slated to close in the first half of 2026, and Cantor Fitzgerald analyst Carter Gould described the price as “borderline immaterial” for Lilly.
Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy adds Wegovy pill at $149 cash price, putting Novo Nordisk’s NVO stock back in play

Amazon Pharmacy said on Friday it now offers Novo Nordisk’s Wegovy weight-loss pill through insurance plans and a cash-pay option, with uninsured customers paying from $149 a month and some commercially insured customers paying $25 for a one-month supply. Amazon said it will add the pill to its pharmacy kiosks in the coming weeks and is working with telehealth firms including WeightWatchers, Wheel and 9amHealth; Novo has said the pill will also be available through CVS, Costco and other telehealth services such as Ro, LifeMD and GoodRx. The U.S. FDA approved the once-daily semaglutide pill in December; semaglutide is the active ingredient in injectable Wegovy and diabetes drug Ozempic, and Reuters said the pill’s success is tied to cash-paying consumers who cannot get coverage.
1 23 24 25 26 27 47
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Uber

NYSE: UBER 93 / 100
#3 BUY ON WEAKNESS

Taiwan Semiconductor

NYSE: TSM 91 / 100
#4 ACCUMULATE

AIG

NYSE: AIG 88 / 100
#5 BUY THE RESET

Ferguson

NYSE: FERG 86 / 100
View full portfolio
Editorial model selection. Not personalised advice.